Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
20 nov. 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
15 nov. 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
17 août 2024 11h27 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel reports Second Quarter 2024 Financial Results and provides Corporate Updates
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
16 août 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel reports Second Quarter 2024 Financial Results and provides Corporate Updates
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
25 juil. 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
Sol-Gel Technologies Announces Management Realignment
15 juil. 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel Technologies Announces Management Realignment
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
28 mai 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
20 mai 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
16 mai 2024 06h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
01 avr. 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream